Human Stem Cell Cloning: 'Holy Grail' or Techno-Fantasy?
By David King,
CNN
| 05. 17. 2013
(CNN) -- Today was a strange day. I'm used to handling the brief but overwhelming burst of media attention that comes with new stories about medical breakthroughs and ethical issues. But I don't often get an accompanying deluge of passionate e-mails and phone calls from people who had read my comments, denouncing me for criticizing science, especially medical research that "can save millions of lives."
There is definitely something special about this idea of "therapeutic cloning," something that has a religious feel to it. Most of those messages come from people who have family members suffering from some of the diseases that we are told will be cured, and it's hard to have to pour cold water on people's hopes.
I feel really angry at the scientists and PR people who have sold the idea of cloned human stem cells to so many patient support groups, when there is so little scientific substance to their promises. We are told that there will be great medical benefits and that the risks that there will be cloned babies are small, but in...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...